Despite a recent share price drop, Guizhou Sanli Pharmaceuti...

Despite a recent share price drop, Guizhou Sanli Pharmaceutical's P/E ratio may still signal bullishness. However, its forecasted growth is lower than the market, causing shareholder discomfort. The low P/E ratio suggests shareholders anticipate no pleasant surprises in future earnings.